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This review summarizes key knowledge regarding the development, growth, and growth disorders of the
adrenal cortex from a molecular perspective. The adrenal gland consists of two distinct regions: the cortex and
the medulla. During embryological development and transition to the adult adrenal gland, the adrenal cortex
acquires three different structural and functional zones. Significant progress has been made in understanding
the signaling and molecules involved during adrenal cortex zonation. Equally significant is the knowledge
obtained regarding the action of peptide factors involved in the maintenance of zonation of the adrenal cortex,
such as peptides derived from proopiomelanocortin processing, adrenocorticotropin and N-terminal proopio-
melanocortin. Findings regarding the development, maintenance and growth of the adrenal cortex and the
molecular factors involved has improved the scientific understanding of disorders that affect adrenal cortex
growth. Hypoplasia, hyperplasia and adrenocortical tumors, including adult and pediatric adrenocortical ade-
nomas and carcinomas, are described together with findings regarding molecular and pathway alterations.
Comprehensive genomic analyses of adrenocortical tumors have shown gene expression profiles associated with
malignancy as well as methylation alterations and the involvement of miRNAs. These findings provide a new
perspective on the diagnosis, therapeutic possibilities and prognosis of adrenocortical disorders.
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Human fetal development of the adrenal cortex
Fetal zone formation. The human adrenal glands develop
from two different embryological tissues. The medulla is
derived from neural crest cells, while the cortex develops from
the intermediary mesoderm. The earliest recognizable form of
the adrenal gland occurs 28-30 days postconception (DPC)
as the adrenogonadal primordium (AGP), which is detected
by the expression of steroidogenic factor 1 (SF-1), also known
as NR5A1 (1). After migration in the dorsolateral direction,
a subset of AGP cells expressing high levels of SF-1 forms the
adrenal primordial (AP) or adrenal fetal zone (FZ). At 6 weeks
of gestational age, the developing AP, located ventrolateral to
the aorta, receives pheochromoblasts derived from neural
crest cells that migrate through the AP cells and differentiate
into the catecholamine-producing chromaffin cells of the
adrenal medulla (2,3). By 50-52 DPC, the AP is encapsulated
in a layer formed by fibroblast-like cells overlying the cortical
zone. Meanwhile, the developing AP displays two zones, the
inner FZ and the outer definitive zone (DZ). The FZ consists of
large eosinophilic cells with characteristics typical of steroido-
genic cells, whereas the DZ consists of small, compact basophilic
cells arranged in clusters with the structural characteristics of
cells in a proliferative state. As gestation advances, cells in
the inner region of the DZ show lipid accumulation in the
cytoplasm, resembling that of active steroidogenic cells with
the capacity for cortisol production. At approximately the
30th week of gestation, the fetal adrenal gland resembles a
rudimentary adrenal gland with zona glomerulosa (ZG)-like
and zona fasciculata (ZF)-like components (4).
Factors involved in the regulation of fetal adrenal
development
The factors involved in the regulatory mechanisms of
fetal adrenal development include SF-1, DAX1, ACTH, CRH
and CRH-homologous peptides, IGF1/2 and WT1. SF-1 is a
crucial factor for the initial development and maturation of
the adrenal cortex. SF-1-knockout mice (5) and some patients
show adrenal aplasia in the absence of SF-1 expression (5,6),
while overexpression of SF-1 in mice results in proliferation
and neoplasia of the adrenal cortex (7). An investigation of
the SF-1 gene revealed a mouse fetal adrenal-specific enhancer
(FAdE) containing binding sites for the transcriptional com-
plex Prep1-Hox9-b-Pbx1 and SF-1. The transcriptional complex
Prep1-Hox9-b-Pbx1 initiates FAdE-mediated SF-1 expression,
which subsequently regulates itself by maintaining FAdE-
mediated SF-1 expression in the AP (8). FAdE is not necessary
in mice after E14.5; however, no enhancer was characterized
in the mouse DZ (9). Whether there is enhancer-mediated SF-1
activity during the FZ/DZ transition in the human adrenal
gland is also not known.
The dosage-sensitive sex reversal-adrenal hypoplasia con-
genita critical region on the X chromosome, gene 1 (DAX1),
also known as Nr0b1, is an orphan nuclear receptor.DOI: 10.6061/clinics/2018/e473s
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It interacts with SF-1 and LRH-1 (liver receptor homolog-1,
NR5A2), and functional studies have shown that DAX-1
is a repressor of SF-1 and LRH-1 (10,11). The biological role
of Dax1 remains unclear. The deletion of exon 2 of Dax1
resulted in animals with normal adrenal function (12); how-
ever, adrenal insufficiency develops with time in aging
Dax1-deleted mice (13). Dax1 is expressed in a population of
stem cells from the adrenal cortex, and its presence represses
differentiation, allowing the expansion of progenitor cells.
Conversely, in the absence of Dax1 and the presence of
adrenocorticotropic hormone (ACTH) stimulation, progenitor
cells differentiate prematurely into steroidogenic cells (14).
Moreover, Dax1 may serve to repress FAdE activity in the
mouse adrenal gland during the FZ to DZ transition (9). In
fact, the regulation of Dax1 expression maintains the balance
between progenitor stem cell renewal and adrenocortical
differentiation, which involves different factors such as SF-1,
ACTH and Wnt signaling (15). Recently, studies in vivo and
in vitro have defined a repressor function of SF-1 SUMOyla-
tion and Dax1 in the physiological interruption of FAdE-
mediated SF-1 expression and the resultant regression of the
mouse X-zone (16).
As the outer DZ emerges, ACTH participates in the regula-
tion of steroidogenesis and the maintenance of the adrenal
cortex. ACTH is essential for morphological and functional
adrenal cortex development after the first trimester in human
pregnancy (17). ACTH is a peptide hormone with 39 amino
acids whose secretion is controlled by a 41-amino acid peptide,
corticotropin-releasing hormone (CRH), in the anterior pitui-
tary. In the adrenal cortex, ACTH binds to melanocortin recep-
tor 2 (MC2R), activating cAMP-dependent protein kinase (PKA)
and ERK/MAPK (18). CRH is produced in the hypothalamus
and stimulates corticotroph cells in the anterior pituitary to
produce a precursor polypeptide with 241 amino acid residues,
proopiomelanocortin (POMC), which produces ACTH (among
other peptides) after cleavage. CRH, the homologous peptides
urocortin (UCN) 1, 2 and 3, and CRH receptors are found in the
FZ and DZ (19) in distinct patterns during adrenal develop-
ment, suggesting local regulation by CRH and related peptides
(20). The role of ACTH in adrenal development is performed
partially through the stimulation of growth factors such as
insulin-like growth factor 1–2 (IGF1 and IGF2), both expressed
in the adrenal gland (21). IGF2 is more highly expressed in the
fetal adrenal gland, whereas IGF1 predominates in the adult
adrenal gland. However, IGF2 is also present (although at
lower levels than in the fetal adrenal gland) in progenitor cells
localized in the outer adult adrenal zone, specifically in capsule
and subcapsule cells (22). Mouse embryos lacking functional
insulin/IGF signaling maintained the AGP in an undifferen-
tiated state and presented complete agenesis of the adrenal
cortex, failure in the testicular genetic program and delay in
ovarian differentiation, demonstrating the crucial role of IGF
signaling in different aspects of AGP development (23). Wilms
tumor suppressor (WT1) is a fundamental factor in the AGP,
as ectopic WT1 expression maintains the AGP in an undiffer-
entiated state, preventing the differentiation of progenitor cells
into steroidogenic cells. Moreover, through the control of WT1,
GATA4, GLI1, and TCF21 expression in the mouse adrenal
cortex, progenitor/stem populations can provide and maintain
steroidogenic cells in the adrenal gland (24).
The extracellular matrix (ECM) could play an important
role during human adrenal gland development (25). The identi-
fication of ECM components and their integrin receptors in
the second-trimester human fetal adrenal gland revealed that
collagen IV was distributed throughout the fetal gland. Laminin
was predominant in the DZ, whereas fibronectin was pre-
dominant in the FZ. Additionally, the a2- and a3-subunits of
integrin were detected at high levels throughout the entire
adrenal cortex, but only the b3-integrin subunit was detected
in chromaffin cells (26), suggesting a specific role during
adrenal gland development. Indeed, experiments using human
fetal adrenal gland cultures showed that the presence of
collagen IV in the matrix substrate increased the effect of ACTH
stimulation on the levels of dehydroepiandrosterone sulfate
(DHEA-S) and cortisol in the culture medium. Moreover, the
presence of fibronectin in the substrate enhanced the secretion
of DHEA-S but impaired that of cortisol (26). In the DZ, laminin
protected cells from apoptosis induced by angiotensin 2
(Ang II), which is consistent with the low level of cell death in
the DZ (27). Moreover, the collagen and laminin expressed
in the DZ can contribute to maintaining the high level of
proliferation needed to ensure fetal adrenal growth (28). Taken
together, these results provide evidence of the contribution of
the extracellular microenvironment not only to plasticity but
also to responsiveness to hormones in human fetal adrenal
gland development.
Transition of the fetal zone to the definitive zone/
adult adrenal cortex
Studies of the transition of the mouse FZ to the DZ and
adult adrenal cortex provide insights into the mechanisms
that regulate this transition. Zubair et al. (8,9,29) concluded
that DZ cells are derived from FAdE-expressing cells of the
FZ. Conversely, findings involving the activation of the sonic
hedgehog (SHH) pathway and its effector Gli1, a marker of
steroidogenic adrenal cell progenitors, provide evidence that
Gli1-positive/SF-1-negative adrenal capsule cells give rise to
the DZ (30).
Research by Wood et al. (31) integrates observations regard-
ing the origin of adrenocortical adult steroidogenic cells from
both the FZ and the adrenal capsule. These studies demon-
strated that subsets of Gli-positive capsular cells are descended
from cells of the FZ that previously expressed SF-1. Moreover,
capsule cells expressing the transcription factor TCF21, a
known inhibitor of SF-1 (32,33), give rise to nonsteroidogenic
stromal adrenocortical cells. These observations indicate the
origin of the adult adrenal cortex from either fetal cortical cells
or fetal cortex-derived capsular cells.
After birth, the FZ undergoes rapid involution by apo-
ptosis (34), combined with differentiation of the DZ and
development of the ZF and ZG, under the influence of the
hypothalamus-pituitary-adrenal (HPA) axis (ACTH), Ang II
and other trophic factors (35). As a consequence, the weight
of the adrenal gland decreases by 50%, and regardless of
gestational age at birth, gland size decreases to its normal
childhood size within two weeks after birth (36). At approxi-
mately 6-9 years old, the zona reticularis (ZR) begins to form
in the inner boundary of the ZF with the medulla, a process
known as adrenarche. Adrenarche is characterized by the
production of adrenal androgens and proliferation of the
ZR (37,38), but the mechanism and control factors are not
completely known. The postnatal mouse adrenal cortex
contains a remnant of the ZF, the X-zone, located adjacent to
the adrenal medulla (39). The X-zone disappears at puberty
in males and during the first pregnancy in females (40).
As the enzyme cytochrome P450 17A1 (Cyp17A1), which
is required for steroidogenic hormones, is absent in the
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adrenals of postnatal mice, the mouse adrenal does not
produce androgens (41).
Human adult adrenal cortex
The structure of the human adrenal cortex. The adult
adrenal gland is composed of two parts, the medulla and the
cortex. The human adult adrenal gland consists of three
compartments with distinct morphological and functional
characteristics called the zona glomerulosa (ZG), zona fascicu-
lata (ZF) and zona reticularis (ZR). The ZG is the outermost and
most compact compartment composed of ovoid cells forming
rosettes similar to glomeruli. These cells, which are also called
aldosterone-producing cell clusters (APCCs), express aldoster-
one synthase (CYP11B2), primarily in the outer layers (42).
Under the ZG lies the ZF, which is composed of large cells in
radial cords that form fascicles and constitute the major part of
the gland. The inner adrenal cortex zone bordering the medulla
is the ZR, which is composed of cords of cells scattered in dif-
ferent directions to form a network.
The adrenal glands are highly vascular and are supplied by
three arteries, the superior, middle and inferior adrenal arteries,
which are ramifications of the phrenic, aortic and renal arteries,
respectively. The adrenal arteries supply the adrenal glands
with approximately 50 arterioles, forming a capsular arteriolar
plexus. This arteriolar plexus projects cord-like sinusoid capil-
laries deeper into the cortex. In the ZR, another sinusoid plexus
is formed that empties into a central vein in the medulla. The
right adrenal vein drains directly to the vena cava, while the
longer left adrenal vein drains into the left renal vein. The rich
innervation of the adrenal glands comes from the celiac plexus
and the abdominopelvic splanchnic nerves of the sympathetic
autonomic nervous system in conjunction with parasym-
pathetic bundles from the phrenic and vagal nerves. After
penetrating the adrenal capsule, they form a subcapsular nerve
plexus whose fibers extend to both the cortex and medulla
surrounding the cells of these regions. The intrinsic innervation
of the adrenal gland arises from ganglion cells distributed in the
subcapsular region, cortex and medulla (43). In the adrenal
medulla alone, the preganglionic sympathetic fibers cross the
paravertebral and prevertebral ganglia without synapsing to
terminate on the postganglionic neurons and chromaffin cells (44).
The function of the human adrenal cortex
The function of the adrenal gland is steroid hormone
production. Three main types of hormones are produced:
glucocorticoids (cortisol, corticosterone), mineralocorticoids
(aldosterone, deoxycorticosterone) and androgens (sex ster-
oids). Cholesterol is the precursor of all adrenal steroid
hormones (45); its principal source is low-density lipoprotein
(LDL) cholesterol uptake by LDL receptors present in adrenal
cells (46). LDL-LDLR is internalized by endocytosis, and the
vesicles formed fuse with lysozymes, where free cholesterol
is produced after hydrolysis. Cholesterol can be generated de
novo from acetyl coenzyme A, and HDL cholesterol can be
utilized through the scavenger receptor class B type 1 (SR-B1) (47).
Mineralocorticoid secretion: the renin-angiotensin-
aldosterone axis
Aldosterone is the primary mineralocorticoid produced by
ZG cells under the principal control of Ang II, potassium
and, to a lesser extent, ACTH. In contrast, somatostatin, heparin,
atrial natriuretic factor, and dopamine inhibit Ang II synthesis.
Angiotensinogen is synthesized in the liver and converted to
angiotensin I (Ang I) by renin in the kidney. Ang I is later
converted to Ang II by angiotensin converting enzyme
(ACE) in the lung. The secretion of aldosterone is restricted to
glomerulosa cells due to the specific presence of the enzyme
aldosterone synthase, CYP11B2 (48). Ang II and potassium
stimulate aldosterone secretion by increasing the transcrip-
tion of CYP11B2, but ACTH has no effect on CYP11B2 gene
or enzyme activity. ACTH increases aldosterone by stimulat-
ing the early steps of the steroidogenesis pathway, contributing
to increased aldosterone. After binding to nuclear mineralo-
corticoid receptors, aldosterone causes increased reabsorption
of sodium and excretion of both potassium and hydrogen ions
in kidney tubules. Other aldosterone target tissues are the colon
and salivary glands.
Glucocorticoid secretion: the hypothalamus-
pituitary-adrenal (HPA) axis
In humans, cortisol is the principal glucocorticoid produced
by the human ZF under the control of ACTH, increasing blood
glucose concentration through its action on glycogen, protein
and lipid metabolism. Glucocorticoids inhibit glucose uptake
in muscles, causing insulin resistance in muscle tissue, and lipol-
ysis in adipose tissue, resulting in the release of fatty acids into
circulation (49). ACTH is synthesized by the anterior pituitary
as part of a 241-amino acid precursor, POMC. ACTH is secreted
by the anterior pituitary under the influence of CRH, arginine
vasopressin (AVP) and some cytokines (50). CRH secretion
from the hypothalamus is regulated by circadian rhythms and
by stressors acting on the hypothalamus, such as hypoglycemia,
hypotension and fever. The secretion of both CRH and ACTH is
inhibited by glucocorticoids in negative feedback control of the
HPA axis.
Adrenal androgen secretion
ZR cells in the human adrenal produce the precursor andro-
gens dehydroepiandrosterone (DHEA), dehydroepiandro-
sterone sulfate (DHEA-S), androstenedione androstenediol and
11b-hydroxyandrostenedione (11OHA) (51). These androgens
have weak activity, but they are precursors for peripheral tissue
conversion to testosterone and estrogens such as estradiol (52).
These androgens and precursor steroids produced in the human
adrenal seem to be stimulated by ACTH (53). In addition, there
is evidence that luteinizing hormone and chorionic gonadotropin
(LH/hCG) could regulate androgen synthesis independently of
ACTH (54). However, the mechanism that regulates the synthesis
of adrenal androgens has not yet been fully characterized.
Maintenance of the adrenal cortex
Sonic hedgehog and Wnt/b-catenin pathways. Several
findings have suggested that cells proliferate in the outer
region of the adrenal cortex (capsule, subcapsule and outer
ZG cells) and migrate to the inner regions during differentia-
tion (inner ZG and ZF cells), while senescence occurs at the
boundary between the cortex and medulla (ZR cells) (55-57).
Two pathways are involved in mouse adrenal gland develop-
ment and maintenance: the Sonic hedgehog (SHH) and Wnt/
b-catenin pathways. In studies utilizing lineage tracing in
mouse embryos, SHH was found in progenitor cells residing
in the subcapsular ZG (30). In adult adrenal glands, SHH-
positive cells colocalize with SF-1 in nonsteroidogenic cortical
cells of the ZG but not in differentiated ZG or ZF cells.
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Both ZG and ZF cells express SF-1; in addition, ZG and ZF
cells express Cyp11b2 and Cyp11b, respectively. All of these
molecules are markers of fully differentiated steroidogenic
cells. Other findings involving the loss of SHH in the adrenal
cortex have shown reduced proliferation of capsular cells and
decreases of 50-70% in the adrenal size of SF-1-Cre mice, who
remain smaller as adults (58). However, the remaining adrenal
cortex maintains its steroidogenic function, indicating that
SHH is not related to the differentiation of the adrenal cortex.
These results implicate the SHH pathway in the maintenance
of the fetal and adult adrenal cortex. In a recently created mouse
model, the transcriptional regulators YAP (Yes-associated
protein) and TAZ (transcriptional coactivator with PDZ-
binding motif), both effectors of the Hippo signaling pathway,
were conditionally deleted in steroidogenic cells (59). Male mice
showed downregulation of SHH, age-dependent degeneration
of the adrenal cortex, an increase in apoptosis and a reduction
in steroidogenic gene expression. In contrast, no gross degene-
rative changes were observed in the adrenal glands of females,
although steroidogenic capacity and SHH expression were
reduced, suggesting an important role for YAP and TAZ in the
maintenance of the postnatal adrenal cortex.
To investigate the role of the Wnt/b-catenin pathway in the
maintenance of the adrenal cortex, mouse Sf1/Cre transgenes
were used to inactivate conditional b-catenin alleles (60).
The analysis of fetal adrenal development after the complete
inactivation of b-catenin showed decreased proliferation in
presumed progenitor cells of the adrenal cortex and adrenal
aplasia. In animals with lesser degrees of b-catenin inactivation,
age-dependent degeneration of the adrenal cortex occurred,
demonstrating the role of the Wnt/b-catenin pathway in
maintaining the fetal and adult adrenal cortex. In contrast,
overactivation of b-catenin produced an increase in progenitor-
like cells and tumor formation. Indeed, the Wnt pathway is
frequently and aberrantly activated in adrenocortical tumors
(61,62).
Effects of ACTH and N-POMC on adrenal
maintenance and proliferation
The elimination of POMC products was shown to prevent
development of the adrenal gland. Yaswen et al. (63), using
mice lacking POMC-derived peptides (i.e., POMC-null mutant
mice), showed defective adrenal development and undetectable
plasma steroids. In another study using POMC -/- mice (64),
adrenal glands were found in all mice, although they had
reduced weight and disrupted cortical architecture compared
with those of wild-type animals. Additionally, plasma corticos-
terone was undetectable, while aldosterone was significantly
reduced. In POMC -/- mice treated for ten days with ACTH,
the adrenal weight, adrenal morphology and plasma corticos-
terone levels were restored.
Estivariz et al. (65,66) tested peptides derived from pro-
gamma-MSH, a smaller N-POMC peptide lacking gamma-
MSH, which proved to be potent mitogens both in vivo and
in vitro. One of them, N-POMC 1–28, was shown to have this
activity. N-POMC 1–28 was isolated from human pituitary
glands, but it was initially considered an artifact because
it was not found in circulation (67). Since then, it has been
tested and shown to be mitogenic in the murine adrenal
gland. The first 28 amino acids of the N-terminal portion of
POMC have been shown to be essential to the mitogenic
activity of N-POMC 1–28 in vivo (68-70) and in vitro (71-73).
Moreover, N-POMC 1–28 peptides prevent atrophy in the
regenerating adrenal gland after hypophysectomy in rats by
preventing the apoptosis of adrenocortical cells (69).
N-POMC 1–49 is an endogenous peptide produced after
the cleavage of pro-gamma-MSH in the intermediary lobe of
the pituitary. In vitro studies demonstrated that this peptide
is mitogenic (71,73); however, in vivo, it does not induce
enlargement of the adrenal gland (74). Previous research
indicates that O-linked glycan must be present for the
N-POMC 1–49 proliferative effect (75). However, this issue
requires further investigation to understand the involvement
of endogenous N-POMC 1–49 in adrenal proliferation and
maintenance.
Although dependence on ACTH and N-POMC peptides is
evident, and these peptides are crucial for maintenance of the
adrenal cortex, other tissue components such as the vascula-
ture (76), and factors such as neurotransmitters (77) may also
have specific roles in this function. There is also the possi-
bility of the integration of medullary, neural and vascular
regulation of cortical function and maintenance as a con-
sequence of the intimate relationship between these adrenal
gland components.
Disorders of adrenal cortex growth
Adrenal hypoplasia. Adrenal hypoplasia is defined by
underdevelopment or hypotrophy of the adrenal cortex as a
consequence of distinct clinical conditions. Adrenal hypo-
plasia can be divided into two categories of disease: primary
and secondary hypoplasia. Primary hypoplasia is character-
ized by hypofunctional and hypotrophic adrenals due to
deficiencies observed in the formation and differentiation of
the adrenal gland; this condition is called congenital adreno-
cortical hypoplasia. Four forms of congenital adrenal hypoplasia
have been identified, as follows: 1) an X-linked form is caused
by a mutation or deletion of the DAX1 gene on the X chromo-
some (78); 2) the autosomal recessive form is due to a mutation
or deletion of the SF-1 gene on chromosome 9q33 (79); 3) a rare
autosomal form includes IMAGE syndrome (80) and SERKAL
syndrome (81), caused by mutations in CDKN1C and WNT4,
respectively; and 4) ACTH resistance syndrome and familial
isolated glucocorticoid deficiency syndromes are autosomal
recessive diseases caused by mutations in genes related to
ACTH function and signaling, such as MC2R and MRAP (82).
Mutations in two other genes have also been associated
with ACTH resistance syndrome, the nicotinamide nucleotide
transhydrogenase (NNT) gene (83) and the minichromosome
maintenance-deficient 4 (MCM4) gene (84). The secondary
form of adrenal hypoplasia is caused by pituitary or hypo-
thalamic dysfunction, such as developmental abnormalities of
the central nervous system, diseases of pituitary development,
isolated ACTH deficiency, defects in POMC processing and
enzyme convertase 1 (PCSK1), and nongenetic causes (85).
These dysfunctions result in deficient ACTH synthesis and
secretion, which culminates in adrenal hypofunction and
hypotrophy due to a lack of adrenal stimulus.
Adrenocortical hyperplasia
Congenital adrenal hyperplasia (CAH). CAH is an inheri-
ted enzymatic deficiency in cortisol synthesis. The deficiency
in cortisol production results in excessive secretion of ACTH,
which in turn cannot block cortisol synthesis, leading to
enlargement of the adrenal gland. The more severe forms
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(i.e., complete enzymatic defect) are called ‘‘classic’’ CAH,
while the milder forms (partial enzymatic defect) are referred
to as ‘‘nonclassic’’ CAH. All CAH forms are autosomal
recessive disorders.
Deficiency in 21-hydroxylase (CYP21A2) is the most
common cause of CAH, accounting for more than 90% of
cases (86). A complete absence of CYP21A2 activity results
in glucocorticoid and mineralocorticoid deficiencies as well
as androgen excess (virilization). Nonclassic CYP21A2 defi-
ciency does not produce adrenal insufficiency but is asso-
ciated with premature puberty, hirsutism, acne, and irregular
menses due to excess androgen. The gene encoding human
CYP21A2 is located on chromosome 6p21.3 inside the human
leukocyte antigen (HLA) major histocompatibility complex
gene (87). Complete deletions, large gene conversions, and
nonsense or frameshift mutations result in compromised
CYP21A2 and the classic form of CYP21A2 deficiency.
In nonclassic CYP21A2 deficiency, the alleles preserve
some enzyme activity as well as cortisol and aldosterone
production (88).
The other form of CAH is 11b-hydroxylase (CYP11B1)
deficiency, which represents approximately 8% of all
CAH cases (89). Patients with this form of CAH also exhibit
decreased cortisol synthesis and adrenal androgen over-
production. In contrast to CYP21A2, patients with CYP11B1
deficiency present with hypertension and sometimes hypo-
kalemia. The CYP11B1 gene is located on chromosome 8q21-
22, approximately 40 kb from the homologous CYP11B2, the
aldosterone synthase gene (90). More than 80 mutations have
been described, but the relationship between genotype and
phenotype remains unclear (91).
3b-Hydroxysteroid dehydrogenase type 2 (3bHSD2) defi-
ciency is characterized by both mineralocorticoid and gluco-
corticoid deficiency as well as dehydroepiandrosterone (DHEA)
production. HSD3B2 is expressed exclusively in the adrenals
and gonads, while HSD3B1, the homologous type I gene, is
expressed in the placenta and peripheral tissues (skin, breast
and prostate) (92). TheHSD3B2 gene is located on chromosome
1p13.1 and consists of four exons. Exons 2–4 are translated into
a protein of 371 amino acids (93). Mutations (nonsense and
frameshift) eliminate enzyme transcription and function,
resulting in salt-wasting forms of 3bHSD2 deficiency, while
single amino acid substitution decreases the affinity of the
enzyme for substrate, leading to non-salt-wasting forms of
3bHSD2 deficiency (94).
Deficiency in 17a-hydroxylase (CYP17A1) is rare and
results in no production of either cortisol or androgens, but
the progesterone and aldosterone pathways are not affected.
CYP17A1 is encoded by a gene located on chromosome 10q24.3
that contains 8 exons encoding a 508 amino acid protein (95).
More than 90 mutations have been described in countries
where CYP17A1 is more prevalent, and specific mutations are
present due to founder effects (96).
The most severe defect in steroidogenesis is lipoid congeni-
tal adrenal hyperplasia (LCAH), in which the patients’ adrenal
glands are greatly enlarged and replete with lipids. This type of
hyperplasia is caused by a defect in the steroidogenic acute
regulatory protein (StAR), which prevents the mobilization
of cholesterol into the mitochondria, resulting in nonsteroid
synthesis. P450-oxidoreductase deficiency combines features of
CYP21A2, CYP17A1 and CYP19A1, which are associated with
different degrees of severity. These patients have different
skeletal malformations that are characteristic of Antley-Bixler
syndrome (97).
Treatments for CAH include glucocorticoid and miner-
alocorticoid therapy as well as some experimental therapies
other than glucocorticoids. However, treatment remains a
major clinical challenge, and no consensus exists among
practitioners (91).
Primary macronodular adrenal hyperplasia (PMAH)
Described for the first time in 1964 (98), PMAH is a rare
cause of Cushing syndrome (CS), accounting for less than 2%
of cases (99). In general, PMAH presents with bilateral macro-
nodules and adrenal enlargement. The macronodules present
with aberrant expression of different ectopic G-protein
coupled receptors, such as gastric inhibitory polypeptide
receptor, luteinizing hormone receptor and serotonin recep-
tors (99,100). The binding of these aberrant receptors to
their ligands mimics the result of ACTH binding to MC2R,
activating the PKA pathway and increasing cortisol produc-
tion (101). Additionally, the presence of ectopic POMC and
ACTH in a subpopulation of cells within the hyperplastic
nodules was described recently in several cases of PMAH in
both tissue (102) and human cell cultures obtained from
PMAH nodules (103). The production of ectopic ACTH in
the nodules is at least partially regulated by the PKA path-
way and may act in autocrine and paracrine manners (103),
allowing a certain independence of cortisol synthesis in
PMAH cells.
The molecular causes of PMAH have not been completely
established, but several studies have tried to find a common
event leading to the formation of macronodules and variable
cortisol secretion. For example, mutations in the GNAS
andMC2R genes have been reported, but they are present in
only a limited number of cases. Recently, frequent germline
mutations in the ARMC5 gene have been reported in different
potentially sporadic and familial cohorts (24-55%), making such
mutations the most frequent molecular abnormality related to
PMAH (104-108). The ARMC5 gene is located on chromosome
16p11.2, and because germline mutations are associated with
nodule-specific somatic mutations, this gene is hypothesized to
be a tumor suppressor gene (104).
Although little is currently known about the function of
ARMC5, its importance in regulating steroidogenesis, pro-
liferation and apoptosis has been described in cell lines and
in PMAH cell cultures (103,104). Additionally, ARMC5 is
important for the embryological development of mice, T cell
differentiation, and immune response (109,110). Finally,
ARMC5 has no enzymatic activity, and its function depends
on interactions with other proteins (109). This interactivity
may explain why it is involved in multiple distinct cellular
mechanisms, as shown in Figure 1.
Adrenal tumors
Adrenocortical tumors (ACTs) are frequent neoplasms
affecting 6-7% of the population (111). Most ACTs are benign,
unilateral and nonfunctioning masses incidentally found
during abdominal imaging in approximately 2% of the
general population; they are designated incidentaloma. When
functional, benign tumors often cause Cushing syndrome
(CS), which originates from chronic exposure to variable
amounts of glucocorticoids, mainly cortisol (112).
Adrenocortical adenomas (ACA)
Cortisol-producing adenomas are characterized by abnor-
mally high levels of cAMP/protein kinase A (PKA) pathway
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activation. PKA is the main regulator of cortisol production
and proliferation in adrenocortical cells (113). PKA is com-
posed of four subunits, two catalytic and two regulatory,
which are bound together under normal conditions. When
cells are stimulated by the binding of ACTH to MC2R, a
G-protein coupled receptor (GPCR), cAMP binds to the regu-
latory subunits and induces release of the catalytic subunits,
which phosphorylate transcription factors in the nucleus,
culminating in the transcription of steroidogenic enzymes
and the synthesis of cortisol (114). Mutations in the gene encod-
ing the alpha catalytic subunit of protein kinase A (PRKACA)
have been reported in 30-65% of adenomas causing overt
CS (115,116). The most frequent mutation described in this
gene, p.Leu206Arg, leads to the replacement of a leucine
residue at position 206 by arginine (117). These mutations
constitutively activate the cAMP pathway, resulting in abnor-
mal PKA activity, increased cortisol production, and tumor
development. According to Lacroix and coworkers (118), the
absence of mutations in the PRKACA gene in cases of low-
cortisol-producing adenomas may explain why they rarely lead
to CS over time (112).
Adrenocortical adenomas have also been associated with
postzygotic mutations in the gene encoding the a subunit of
the stimulatory guanine nucleotide-binding protein (GNAS).
These mutations are normally associated with McCune-Albright
syndrome (MAS), where mosaic gain-of-function GNAS muta-
tions in patients with MAS lead to the constitutive activation of
adenylyl cyclase and to clinical features such as fibrous dysplasia
and cafe-au-lait skin pigmentation (119).
Although the mechanisms leading to the development
of adrenocortical adenomas have not yet been completely
identified, mutations in the PRKACA gene are considered
the primary genetic alterations involved in the formation of
these tumors through the cAMP/PKA signaling pathway,
stimulating both cortisol secretion and cell proliferation.
Similar to adrenocortical adenomas, aldosterone-producing
adenomas (APAs) are benign functional adrenocortical lesions.
The mutations found in APAs are mostly related to the regu-
lation of calcium and potassium channels, such as the somatic
mutations found in ATPA1A, a gene encoding the alpha
subunit of the sodium/potassium ATPase, and ATP2B3,
a gene encoding the plasma membrane calcium-transporting
ATPase3 (120). Additionally, mutations in KCNJ5, which
encodes potassium channels, were found in both sporadic
and familial APA cases (121-123). These mutations damage
the channel’s permeability, allowing the entrance of sodium—
instead of potassium—into the cell, resulting in depolarization.
Adult adrenocortical carcinomas
Adult adrenocortical carcinomas (ACCs) are rare tumors,
with an incidence of 1-2 cases per million, that primarily
affect adults over 40 years and are more frequent in women
(124-126). ACCs may be associated with hereditary disorders
such as Li-Fraumeni syndrome, multiple endocrine neoplasia
type 1 (MEN1) and Lynch syndrome, which has a prevalence
between 1-7% in patients with ACCs (127-129). ACCs are
differentiated from ACAs by the presence of 3 or more Weiss
criteria, including nuclear grade, mitotic rate, the presence
of atypical mitoses,o25% clear cells, necrosis,433% diffuse
architecture, and vascular, sinusoid and capsule invasion
(130,131). ACC can produce aldosterone, cortisol, androgens
or estrogens, as described in Table 1 (132,133). Alterations in
the steroidogenic profile can be identified by urine tests for
the diagnosis and follow-up of patients (129,134-136). The
probability of the recurrence of ACC decreases when there
is complete surgical resection of the adrenocortical mass
(137,138). An adjuvant treatment for patients with ACC is the
administration of mitotane (dichlorodiphenyldichloroethane,
o,p’-DDD), whose accepted levels range from 14-20 mg/dl and
whose common tolerated dose is 3-4 g per day (126).
There are well-established molecular markers of great clinical
importance for adrenocortical tumors. Insulin-like growth
factor (IGF2) expression is associated with a malignant ACC
phenotype (139). In fact, it was shown in vitro that IGF2
Figure 1 - Steroidogenesis in adrenocortical cells is regulated by the binding of ACTH to MC2R, activating PKA pathway through the
release of the catalytic subunit (C) by the action of cAMP in specific domains of the PKA, followed by the phosphorylation of transcrip-
tion factors (TFs) in the nucleus that will increase the transcription of steroidogenic enzymes, leading to cortisol production. In addition
to this classic signaling, PMAH cells can be abnormally regulated by aberrant receptors that mimic the action of ACTH when activating
PKA; additionally, the activation of PKA regulates the production of ectopic ACTH within the hyperplastic nodules that will once again
activate PKA independently of pituitary ACTH, allowing a certain independency to cell steroidogenesis. Additionally, mutations in
ARMC5 are the main molecular events associated with PBMAH; ARMC5 decreases steroidogeneis, induces cell apoptosis and might also
be involved in cell proliferation by mechanisms so far unknown.
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induces proliferation, but its overexpression does not modify
the phenotypic and molecular features of ACC cells (140).
In contrast, a study that assessed IGF2 protein expression and
overall survival (OS) found that high IGF2 expression is
associated with longer OS, suggesting that IGF2 is not a
prognostic factor for ACC progression or metastasis (141). Only
in adult ACTs were differences in IGF2 expression observed
between ACA and ACC, while in pediatric ACTs, the IGF1R
gene was overexpressed in carcinomas (142). Inhibition of the
IGF signaling pathway has been proposed as a promising
treatment (142), and in combination with the administration of
mitotane, it reduces tumor growth (143). Moreover, the methyl-
ation levels of the IGF2 promoter region may be a marker for
distinguishing different types of ACTs (144).
Alterations in the Wnt/b-catenin signaling pathway are
associated with gastric and ovarian cancer, gastrointestinal
stromal and myeloid tumors and teratocarcinosarcomas (145-149).
The anomalous expression of b-catenin protein, characterized
by its accumulation in the cytoplasm and/or displacement to
the nucleus, is a common finding in ACTs (150). This abnor-
mality occurs in 77% of ACC cases and 38% of ACA cases;
however, the expression of b-catenin is diffuse only in ACC (150).
Other studies have found no prevalence of b-catenin protein
or gene expression in ACC or ACA (151-152). In addition,
b-catenin expression is not useful for predicting malignancy in
ACCs (151). However, inhibition of the Wnt/b-catenin signal-
ing pathway reduces cell viability and could be a treatment
option for ACC patients (153).
ZNRF3 (zinc and ring finger 3) is an E3 ubiquitin ligase
capable of negatively regulating the Wnt/b-catenin signaling
pathway (154). The ZNRF3 gene is amplified and exhibits
homozygous deletions and mutations in ACCs (155,156). In a
global study, the ZNRF3 gene displayed the most frequent
genetic alterations, suggesting that ZNRF3 is a tumor sup-
pressor in ACCs (155).
In comprehensive molecular studies, TP53 was the gene
with the highest rate of genetic alterations in the analyzed
groups (156,157). The R337H germline mutation in the TP53
gene is an important molecular marker in pediatric tumors. It
is present in only 13.5% of adult patients with ACTs; how-
ever, such mutations are associated with poor prognosis (158).
ACCs usually exhibit high expression of Ki67 protein, a
marker of proliferating cells (159,160) that has been analyzed
together with histopathological markers (161). Using a large
group of patients with ACC, Ki67 was identified as the factor
that most accurately d recurrence in patients who underwent
complete surgical resection (162). Moreover, Ki67 is con-
sidered a predictor of disease-free time and OS (160).
Despite being involved in steroidogenesis, SF-1 exhibits no
differential expression between functioning and nonfunction-
ing adrenocortical tumors (163). SF-1 copy number and SF-1
protein expression are not determining factors in carcinomas,
with increased expression in 10% and 19% of cases, respectively
(163). SF-1 is regulated by dosage-sensitive sex reversal-adrenal
hypoplasia congenita critical region on the X chromosome,
gene 1 (DAX-1) and by upstream stimuli 1 and 2 (USF-1 and
USF-2) (10,164). Another factor that regulates SF-1 is transcrip-
tion factor 21 (TCF21/POD1), which binds to the proximal E-box
region of SF-1 and negatively regulates the expression of both
SF-1 and the cholesterol-transporting protein StAR (32,33,165).
In adult ACTs, TCF21 is expressed at a lower level in ACC than
in ACA or normal adrenocortical tissue (33,166). In ACC,
TCF21 expression is negatively correlated with the cell cycle,
mRNA surveillance and glycosaminoglycan biosynthesis-
heparan sulfate pathways. The cell cycle parameter was the
most significant, including effects on the genes BUB1B and
CDK1 (33).
Recent wide-ranging molecular studies have shown new
genetic alterations that define a distinct profile of ACCs
(155,157). An analysis of 91 ACC cases identified mutated
genes as well as loss of heterozygosity (LOH) and increased
copy number, which are common genetic alterations in ACCs.
Key genes found altered in ACCs included TP53, b-catenin
(CTNNB1) and telomerase reverse transcriptase (TERT) (157).
These recently highlighted genetic alterations are summarized
in Table 2.
Carcinomas have significantly different methylation levels
from metastasis masses, adenomas and normal tissues;
in general, carcinomas are hypomethylated compared to
adenomas (167). Methylation levels and their association with
gene downregulation have been investigated as predictors
of prognosis in adult ACCs (168). In a comprehensive study,
212 CpG islands were found to be hypermethylated in ACCs
compared to ACAs. Moreover, upon demethylation treatment
in H295R adrenocortical carcinoma cells, the hypermethylated
genes showed increased gene expression (169).
Small noncoding RNA molecules (miRs) modulate the
expression of target genes by degrading mRNA posttran-
scriptionally or by inhibiting translation (170). Two separate
studies have shown the potential of miRs as potential bio-
markers in ACC, and miR profiles have been characterized in
ACC (171,172). miR-195 and miR-483-5p (which map to the
second intron of the IGF2 gene) have been shown to have
predictive value for outcomes in ACC patients (173,174).
Another group found that miR-483-5p and miR-34a are
candidate serum biomarkers for adrenocortical tumors, with
74% and 81% accuracy, respectively (175). More recently,
a quantitative real-time assay was developed to measure
miR483 and miR483-5p levels (as a liquid biopsy component)
in plasma samples from 27 patients with ACC (176). The
miR483-5p level was able to predict recurrence but not OS.
In addition, miR483 and miR483-5p levels correlated with
the number of circulating tumor cells (CTCs) detected in the
same blood samples. In another study, the miRNA profile of
ACTs showed 95% accuracy for discrimination between ACC
and ACA (177). An miRNA profile of adrenocortical tumors
based on multiple studies is presented in Table 3 (173-175,
177-180).
Table 1 - Endocrine features of functional ACCs.
Secretion Incidence Symptoms References
Aldosterone rare Hypertension, heart disease Vilela and Almeida (132), Akerstrom et al. (133)
Cortisol 50%-80% Osteoporosis, diabetes mellitus, muscle weakness, plethora Else et al. (129)
Androgen 40%-60% Increased libido, acne, male baldness, virilization, hirsutism,
and menstrual abnormalities
Young (134), Else et al. (129)
Estrogen 1%-3% Gynecomastia, testicular atrophy Else et al. (129)
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Long noncoding RNAs (lncRNAs) in adrenocortical tumors
display tissue-specific expression and may be involved in
transcriptional regulation and silencing (181,182). The lncRNA
profile showed differential expression of 85 lncRNAs between
carcinomas and adenomas. In comparison with normal adrenal
tissue, 956 lncRNAs were differentially expressed in ACC,
including GAS5, H19, MALAT1 and PRINS (183).
Pediatric adrenocortical tumors
A dramatic remodeling of the adrenal cortex structure
takes place after birth, with massive apoptosis of the FZ and,
simultaneously, a progressive differentiation into distinct zones
of adult adrenal cortex. Therefore, adrenocortical pediatric
malignancies may be considered a disturbance of the normal
development process. Pediatric adrenocortical tumors are a
rare malignity, with a worldwide incidence estimated at
0.3/million/year, and are more frequent in girls than in boys.
The incidence is higher in children under 5 years of age and
above 10 years of age, and they exhibit virilization symptoms
that may be associated with CS. The Weiss score system for
adult ACTs is well established (184); however, in children, the
ACT pathological criteria for malignancy remain uncertain
(185). Certain criteria are prognostically favorable, such as a
tumor grade of stage I at diagnosis, patient age under 4 years,
tumor weight p200 g, volume o200 cm3, and symptoms
limited to virilization only (186).
Pediatric adrenocortical tumors are more frequently
associated with Beckwith-Wiedemann syndrome (187,188)
and Li-Fraumeni syndrome (LFS) (189,190). Beckwith-Wie-
demann syndrome causes adrenocortical hyperplasia and
various neoplasms with variable malignancy. It is caused
by genetic defects such as uniparental disomy in the 11p15
chromosomal region (191), whose consequence is the over-
expression of IGF2.
LFS is a familial cancer predisposition disorder caused
by germline mutations in the tumor suppressor gene TP53.
LOH on chromosomes 11 and 17 is the hallmark of pediatric
adrenocortical tumors associated with germline TP53 muta-
tions (192). However, approximately 50% of pediatric ACTs
do not harbor TP53 mutations. Recently, Pinto et al. (192)
showed that CTNNB1 mutations occurred almost exclu-
sively in pediatric ACTs without germline TP53 mutations.
The high incidence of childhood ACT in LFS suggests that
Table 2 - Summary of genetic alterations in comprehensive studies.
Type of alteration Gene Chromosome References
Gene mutation TP53 Tumor protein p53 17p13.1 Zheng et al. (157)
CTNNB1 Catenin beta 1 3p22.1
MEN1 Menin 1 11q13.1
RPL22 Ribosomal protein L22 1p36.31
PRKAR1A Protein kinase cAMP-dependent type 1 regulatory subunit alpha 17q24.2
NF1 Neurofibromin 1 17q11.2
Loss of heterozygosity ZNRF3 Zinc and ring finger 3 22q12.1
RB1 RB transcriptional corepressor 1 13q14.2
CDKN2A Cyclin-dependent kinase inhibitor 2A 9p21.3
Increased copy number CDK4 Cyclin-dependent kinase 4 12q14.1
CCNE1 Cyclin E1 19q12
TERT Telomerase reverse transcriptase 5p15.33
TERF2 Telomeric repeat binding factor 2 16q22.1
Altered expression MED12 Mediator complex subunit 12 Xq13.1 Assie et al. (155)
DAXX Death domain-associated protein 6p21.32
ZNRF3 Zinc and ring finger 3 22q12.1
Hypermethylation CDKN2A Cyclin-dependent kinase inhibitor 2A 9p21.3 Fonseca et al. (167)
GATA4 GATA binding protein 4 8p23.1
BCL2 Apoptosis regulator 18q21.33
DLEC1 Deleted in lung/esophageal cancer 1 3p22.2
HDAC10 Histone deacetylase 10 22q13.33
PYCARD PYD and CARD domain containing 16p11.2
SCGB3A1 Secretoglobin family 3A member 1 5q35.3
Table 3 - miRNA in ACC.
miRNA Objective References
miR-503, miR-1202, and miR-1275 Prognostic value Ozata et al. (178)
miR-483, miR-195, and miR-497 Diagnostic value Ozata et al. (178)
miR-483-5p Diagnostic value Patterson et al. (179)
Patel et al. (175)
miR-195 and miR-100 Biomarker in ACCs Patterson et al. (179)
miR-675 and miR-335 Diagnostic value Schmitz et al. (180)
miR-195 and miR-483-5p Prognostic value Chabre et al. (174)
Soon et al. (173)
MiR-34a Diagnostic value Patel et al. (175)
miR-503-5p, miR-483-3p, miR-450a-5p, miR210, miR-483-5p, miR-421 Diagnostic value Koperski et al. (177)
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the absence of TP53 may lead to increased proliferative cap-
ability, promoting further mutations, clonal expansion and
tumorigenesis.
In southern Brazil, the incidence of TP53 germline muta-
tions is estimated to be between 3.4 and 4.2 per million
children (193). Ribeiro et al. (194) demonstrated that a TP53-
specific mutation, p.R337H, was related to a high prevalence
of these tumors. A founder effect is responsible for the dis-
semination of the TP53/p.R337H mutation in Brazil (195).
Although pediatric adrenocortical tumors are highly asso-
ciated with germline TP53 mutations, only approximately
4% of these cases develop tumors, suggesting other genetic
alterations. A genomic study (192) showed that select cases
with an R337H mutation presented with secondary genetic
events, such as initial LOH on chromosomes 11 and 17p,
followed by dysregulation of IGF2 expression and the acqui-
sition of ATRX (a DNA helicase) mutations (192). Another
finding is LOH of the 11p15 region, leading to IGF2 over-
expression from the paternal allele. Transgenic mouse models
demonstrate that IGF2 overexpression is not sufficient to
promote adrenocortical tumors (196); such promotion occurs
only in cooperation with b-catenin (197).
The most common alteration found in pediatric adreno-
cortical tumors was the amplification and gain of chromo-
some 9q34 close to where the NR5A1/SF-1 gene is situated
(198). In pediatric ACTs, the SF-1 gene is amplified, and the
SF-1 protein is overexpressed, but this alteration seems to be
unrelated to malignancy (199,200).
Strongly downregulated genes in pediatric ACT include
3-b-hydroxysteroid dehydrogenase (HSD3B2) (201), a stero-
idogenic enzyme expressed in the ZG and ZR, which is
involved in aldosterone and cortisol synthesis. This finding
reinforces the hypothesis of disturbances in fetal differentia-
tion. Another downregulated gene is NOV/CCN3, which
encodes a protein with proapoptotic function in adrenocortical
cancer cells, suggesting that a deficient regression process in the
FZ may be part of tumor formation (202).
A set of miRNAs that are differentially regulated in pediatric
ACT has been identified, including miR-99a and miR-100,
which are downregulated. Functional analysis of these miRNAs
has shown that they are able to downregulate expression of
the insulin-like growth factor-mammalian target of rapamycin
(mTOR)-raptor signaling pathway (203). This pathway is
upregulated in childhood ACT, and its inhibition decreases
adrenocortical cell proliferation (204,205).
Pediatric adrenocortical tumors differ from adult ACT
in their origin, molecular alteration and evolution. The
identification of molecular and pathway markers is still a
challenge; however, genomic analyses of genetic alterations
and gene expression profiles provide important new insights
into the pathogenesis and molecular classification of pedia-
tric ACT (192).
Adrenocortical disorders result from misregulation of the
adrenal cortex, generally leading to abnormal growth of the
adrenal glands. However, each abnormality described in this
review has its own unique molecular basis, which makes the
diagnosis and treatment of patients challenging. The use of
whole-genome sequencing to identify genes that can regulate the
appearance or even the severity of adrenocortical diseases has
led to a number of discoveries, especially related to ACC, ACA
and PMAH. The recent description of several molecular markers
in ACCs and the ARMC5 gene in large cohorts of patients
diagnosed with PMAH has allowed researchers to identify
the pathways involved in the development of these tumors.
In the future, these findings may make it possible to target
molecular alterations in a subset of patients with particular
molecular profiles and thus control the abnormal growth of
these adrenal masses.
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